fentanyl transmucosal and pentobarbital both maximize sedation. Keep away from or Use Alternate Drug. Restrict use to clients for whom alternate treatment choices are inadequate
pentobarbital will reduce the extent or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unknown.
pentobarbital will lessen the extent or result of nilotinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
Monoamine oxidase inhibitors (MAOI) may possibly inhibit barbiturate metabolism and prolong barbiturate effects; observe closely
With therapeutic doses of TCAs, barbiturates improve metabolism and decrease blood concentrations of TCAs.
Observe Closely (1)pentobarbital will lessen the extent or outcome of gefitinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will minimize the extent or outcome of loratadine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital will decrease the extent or effect of etoposide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
Contraindicated (one)pentobarbital will lessen the level or effect of dienogest/estradiol valerate by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Ladies mustn't pick out estradiol valerate/dienogest as their contraceptive though employing powerful CYP3A4 inducers as a consequence of probable decrease in contraceptive efficacy.
pentobarbital will decrease the level or influence of alosetron by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unfamiliar.
pentobarbital and daridorexant both boost sedation. Modify Therapy/Monitor Carefully. Coadministration raises threat of CNS depression, which may lead to additive impairment of psychomotor overall performance and result in daytime impairment.
Keep an eye on Closely (two)pentobarbital will lessen the level or effect of suvorexant by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potent CYP3A4 inducers may possibly reduce suvorexant efficacy; if increased suvorexant dose demanded, tend not to exceed 20 mg/working day
pentobarbital will lower the extent or impact of etravirine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital raises read more toxicity of methoxyflurane by growing metabolism. Contraindicated. Elevated metabolism of methoxyflurane to nephrotoxic compounds.